Literature DB >> 16100469

Delirium and extrapyramidal symptoms due to a lithium-olanzapine combination therapy: a case report.

Cengiz Tuglu1, Esin Erdogan, Ercan Abay.   

Abstract

We report an elderly patient who developed severe delirium and extrapyramidal signs after initiation of lithium-olanzapine combination. On hospital admission, serum levels of lithium were found to be 3.0 mM/L which were far above toxic level. Immediate discontinuation of both drugs resulted in complete resolution of most of the symptoms except for perioral dyskinesia which persisted for three more months. We critically discussed the differential diagnosis of lithium intoxication and assessed confounding factors which induce delirium and extrapyramidal signs related with combination therapy of lithium and olanzapine.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16100469      PMCID: PMC2782173          DOI: 10.3346/jkms.2005.20.4.691

Source DB:  PubMed          Journal:  J Korean Med Sci        ISSN: 1011-8934            Impact factor:   2.153


  27 in total

1.  Quetiapine-related tardive dyskinesia.

Authors:  S N Ghaemi; J Y Ko
Journal:  Am J Psychiatry       Date:  2001-10       Impact factor: 18.112

2.  A patient with lithium intoxication developing at therapeutic serum lithium levels and persistent delirium after discontinuation of its administration.

Authors:  Naoto Omata; Tetsuhito Murata; Masao Omori; Yuji Wada
Journal:  Gen Hosp Psychiatry       Date:  2003 Jan-Feb       Impact factor: 3.238

3.  A case of Parkinsonism due to lithium intoxication: treatment with Pramipexole.

Authors:  Carlo Dallocchio; Paolo Mazzarello
Journal:  J Clin Neurosci       Date:  2002-05       Impact factor: 1.961

4.  Nonketotic hyperosmolar syndrome from olanzapine, lithium, and valproic acid cotreatment.

Authors:  Po See Chen; Yen Kuang Yang; Tzung Lieh Yeh; Ya Chen Lo; Yu Ting Wang
Journal:  Ann Pharmacother       Date:  2003-06       Impact factor: 3.154

5.  New-onset diabetes and ketoacidosis with atypical antipsychotics.

Authors:  Daniel R Wilson; Leo D'Souza; Nibar Sarkar; Michael Newton; Connie Hammond
Journal:  Schizophr Res       Date:  2003-01-01       Impact factor: 4.939

6.  [Delirium syndrome as a side-effect of lithium in normal lithium levels].

Authors:  R Niethammer; A Keller; M Weisbrod
Journal:  Psychiatr Prax       Date:  2000-09

7.  Olanzapine-induced rhabdomyolysis.

Authors:  C J Rosebraugh; D A Flockhart; S U Yasuda; R L Woosley
Journal:  Ann Pharmacother       Date:  2001-09       Impact factor: 3.154

Review 8.  Lithium treatment at 52.

Authors:  M Schou
Journal:  J Affect Disord       Date:  2001-12       Impact factor: 4.839

Review 9.  Olanzapine. Pharmacokinetic and pharmacodynamic profile.

Authors:  J T Callaghan; R F Bergstrom; L R Ptak; C M Beasley
Journal:  Clin Pharmacokinet       Date:  1999-09       Impact factor: 6.447

10.  Lithium neurotoxicity: the development of irreversible neurological impairment despite standard monitoring of serum lithium levels.

Authors:  Emma J Lang; Stephen M Davis
Journal:  J Clin Neurosci       Date:  2002-05       Impact factor: 1.961

View more
  5 in total

1.  Valproate and high dosage of zotepine induced acute delirium: a case report.

Authors:  Wen-Yu Hsu; Su-Yin Kuo; Si-Sheng Huang; Ting-Gang Chang; Nan-Ying Chiu
Journal:  Br J Clin Pharmacol       Date:  2012-03       Impact factor: 4.335

2.  Delirium due to a drug-drug interaction of lithium and an NSAID.

Authors:  R A Faaij; G Ziere; R Zietse; T J M Van der Cammen
Journal:  J Nutr Health Aging       Date:  2009-03       Impact factor: 4.075

3.  Delirium associated with olanzapine therapy in an elderly male with bipolar affective disorder.

Authors:  Ravi C Sharma; Ashish Aggarwal
Journal:  Psychiatry Investig       Date:  2010-05-18       Impact factor: 2.505

Review 4.  Drug Interactions with Lithium: An Update.

Authors:  Patrick R Finley
Journal:  Clin Pharmacokinet       Date:  2016-08       Impact factor: 6.447

5.  Safety of Off-Label Pharmacological Treatment in Pediatric Neuropsychiatric Disorders: A Global Perspective From an Observational Study at an Italian Third Level Children's Hospital.

Authors:  Maria Sole Giurin; Marta Paulina Trojniak; Anna Arbo; Marco Carrozzi; Giuseppe Abbracciavento; Lorenzo Monasta; Caterina Zanus
Journal:  Front Pharmacol       Date:  2022-04-12       Impact factor: 5.988

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.